Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris (ACCESS I)

This study has been completed.
Sponsor:
Information provided by:
Galderma
ClinicalTrials.gov Identifier:
NCT00688064
First received: May 28, 2008
Last updated: March 31, 2010
Last verified: March 2010
Results First Received: February 23, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Severe Acne Vulgaris
Interventions: Drug: Adapalene BPO Gel associated with Doxycyline Hyclate
Drug: Vehicle Gel associated with Doxycycline Hyclate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment period: 18 AUG 2008 to 14 NOV 2008 in thirty-five centers (30 in the USA and 5 in Canada) public or private practices. Twenty-five USA centers and four Candadian centers used a central IRB, and the others used a local IRB.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Adapalene-BPO + Doxycycline Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Doxycyline Hyclate 100 mg tablet.
Vehicle + Doxycycline Vehicle Gel associated with Doxycycline Hyclate 100 mg tablet

Participant Flow:   Overall Study
    Adapalene-BPO + Doxycycline   Vehicle + Doxycycline
STARTED   232   227 
COMPLETED   211   201 
NOT COMPLETED   21   26 
Protocol Violation                0                1 
Adverse Event                2                4 
Withdrawal by Subject                7                7 
Lost to Follow-up                10                10 
Lack of Efficacy                0                1 
Pregnancy                1                0 
Any other reasons                1                3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Adapalene-BPO + Doxycycline Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Doxycyline Hyclate 100 mg tablet.
Vehicle + Doxycycline Vehicle Gel associated with Doxycycline Hyclate 100 mg tablet
Total Total of all reporting groups

Baseline Measures
   Adapalene-BPO + Doxycycline   Vehicle + Doxycycline   Total 
Overall Participants Analyzed 
[Units: Participants]
 232   227   459 
Age 
[Units: Participants]
     
<=18 years   152   156   308 
Between 18 and 65 years   80   71   151 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 18.6  (5.84)   18.1  (4.92)   18.4  (5.41) 
Gender 
[Units: Participants]
     
Female   108   97   205 
Male   124   130   254 
Region of Enrollment 
[Units: Participants]
     
United States   170   164   334 
Puerto Rico   18   18   36 
Canada   44   45   89 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent Change From Baseline in Total Lesion Counts at Week 12.   [ Time Frame: Week 12 ]

2.  Secondary:   Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.   [ Time Frame: Week 12 ]

3.  Secondary:   Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12   [ Time Frame: Week 12 ]

4.  Secondary:   Success Rate on the Investigator's Global Assessment   [ Time Frame: Week 12 ]

5.  Secondary:   Percent of Subjects With Adverse Events   [ Time Frame: Up to 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Jean-Charles Dhuin, Clinical Project Manager
Organization: Galderma
phone: +33 4 92 95 29 21
e-mail: jean-charles.dhuin@galderma.com



Responsible Party: Jean-Charles DHUIN Clinical Trial Manager, Galderma
ClinicalTrials.gov Identifier: NCT00688064     History of Changes
Other Study ID Numbers: RD.03.SPR.29074
Study First Received: May 28, 2008
Results First Received: February 23, 2010
Last Updated: March 31, 2010
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
Canada: Health Canada
Canada: Ethics Review Committee